Outcomes of conservative treatment for thoracic vascular graft infections
European Journal of Cardio-Thoracic Surgery · 2025
DOI: 10.1093/ejcts/ezaf171 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Cardio-Thoracic Surgery, 2025. Verfasst von Mathias Van Hemelrijck und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiac Surgery, University Hospital Zurich, Zurich, Switzerland. Hauptthemen laut MEDLINE: Conservative Treatment, Prosthesis-Related Infections, Anti-Bacterial Agents, Blood Vessel Prosthesis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Swiss National Science Foundation.
Abstract (Originalsprache)
OBJECTIVES Thoracic vascular graft infections are devastating complications after aortic surgery, entailing high mortality. The gold standard treatment combines excisional surgery and antimicrobial therapy, but patients deemed inoperable might benefit from a conservative approach. Outcomes of patients treated only with antimicrobial agents without reoperative surgery are scanty. We aim to describe patients’ characteristics and outcomes using an antibiotic-only strategy without thorough debridement. METHODS Retrospectively collected data from a prospective cohort in a tertiary centre. Descriptive analysis for baseline characteristics and Kaplan–Meier estimates for survival were performed. RESULTS From November 2012 to December 2022, 66 patients were identified with aortic root, ascending aortic and aortic arch graft infections. Of these, 44 received an antibiotic-only strategy or in combination with selective debridement after achieving multidisciplinary consensus. Median follow-up was 4.8 years [interquartile range (IQR) 1.7–6.1], and cumulative survival was 82.9% (CI 95%, 69.7–96.1). Streptococcus spp were the most common isolated microorganisms. CONCLUSIONS In selected cases, a conservative approach with antibiotics only or in combination with selective debridement showed acceptable results at follow-up, suggesting a valuable therapy option for this cohort of patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiac Surgery, University Hospital Zurich, Zurich, Switzerland.
- Department of Nuclear Medicine, Cardiac Imaging, University Hospital Zurich, Zurich, Switzerland.
- Department of Cardiology, University Hospital Zurich, Zurich, Switzerland.
- Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.
- Center for Translational and Experimental Cardiology (CTEC), University of Zurich, Zurich, Switzerland.
ORCID-Profile: Mathias Van Hemelrijck, Juri Sromicki, Petar Risteski, Ronny R Buechel, Barbara Hasse, Héctor Rodríguez Cetina Biefer, Omer Dzemali
Förderung
- Swiss National Science Foundation
Zitieren
APA
Van Hemelrijck, M., Sromicki, J., Risteski, P., Boulos, R., Buechel, R. R., Frank, M., Hasse, B., Rodríguez Cetina Biefer, H., Dzemali, O., & VASGRA Cohort (2025). Outcomes of conservative treatment for thoracic vascular graft infections. European Journal of Cardio-Thoracic Surgery. https://doi.org/10.1093/ejcts/ezaf171
Vancouver
Van Hemelrijck M, Sromicki J, Risteski P, Boulos R, Buechel RR, Frank M, et al. Outcomes of conservative treatment for thoracic vascular graft infections. European Journal of Cardio-Thoracic Surgery. 2025. doi:10.1093/ejcts/ezaf171
BibTeX
@article{VanHemelrijck2025,
author = {Van Hemelrijck, Mathias and Sromicki, Juri and Risteski, Petar and Boulos, Rasha and Buechel, Ronny R and Frank, Michelle and Hasse, Barbara and Rodríguez Cetina Biefer, Héctor and Dzemali, Omer and VASGRA Cohort, VASGRA Cohort},
title = {Outcomes of conservative treatment for thoracic vascular graft infections},
journal = {European Journal of Cardio-Thoracic Surgery},
year = {2025},
doi = {10.1093/ejcts/ezaf171}
}
EUVIMED